Clene Business Summary

Clene Inc. (CLNN) is a late clinical-stage biopharmaceutical company that generates revenue primarily through the commercialization of dietary supplements and strategic capital raises, while its core value driver remains its proprietary electro-crystal-chemistry drug development platform. The company operates through two primary segments: the development of clean-surfaced nanotechnology (CSN) therapeutics for neurodegenerative diseases and a smaller commercial dietary supplement business. Its lead asset, CNM-Au8, is currently undergoing Phase 2/3 trials for amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disease, with a focus on improving mitochondrial health and neuronal function. Clene competes directly with biopharmaceutical firms such as Denali Therapeutics, Amylyx Pharmaceuticals, and Biogen, positioning itself as a specialized nanotechnology player seeking accelerated FDA approval pathways based on neurofilament light chain (NfL) biomarker data. The company was co-founded by Robert Knell, Dallas Hack, and Reed N. Wilcox, with Rob Etherington serving as the founding President and CEO. Etherington brings over 30 years of industry experience, including a significant tenure at Actelion Pharmaceuticals and leadership roles at Parke-Davis/Pfizer. The executive team is further bolstered by Chief Science Officer Mark Mortenson, a nanotechnology expert and co-founder of General Resonance, and Head of Medical Dr. Benjamin Greenberg, an internationally recognized neurology professor from UT Southwestern. Clene’s strategic direction is overseen by Chairman David J. Matlin, co-founder of MatlinPatterson Global Advisers, and the board includes notable representatives from Kensington Capital Holdings. Recent institutional backing includes significant investments from Boxer Capital and Coastlands Capital, which extend the company’s operational runway through late 2026.